AT260974T - Transgenic, non-human mammal that shows the amyloid-forming pathology of alzheimer's disease - Google Patents

Transgenic, non-human mammal that shows the amyloid-forming pathology of alzheimer's disease

Info

Publication number
AT260974T
AT260974T AT91912653T AT91912653T AT260974T AT 260974 T AT260974 T AT 260974T AT 91912653 T AT91912653 T AT 91912653T AT 91912653 T AT91912653 T AT 91912653T AT 260974 T AT260974 T AT 260974T
Authority
AT
Austria
Prior art keywords
amyloid
alzheimer
transgenic
disease
shows
Prior art date
Application number
AT91912653T
Other languages
German (de)
Inventor
Barbara Cordell
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US53885790A priority Critical
Application filed by Scios Inc filed Critical Scios Inc
Priority to PCT/US1991/004447 priority patent/WO1991019810A1/en
Publication of AT260974T publication Critical patent/AT260974T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Humanized animals, e.g. knockin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0306Animal model for genetic diseases
    • A01K2267/0312Animal model for Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/15Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian
AT91912653T 1990-06-15 1991-06-17 Transgenic, non-human mammal that shows the amyloid-forming pathology of alzheimer's disease AT260974T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US53885790A true 1990-06-15 1990-06-15
PCT/US1991/004447 WO1991019810A1 (en) 1990-06-15 1991-06-17 Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease

Publications (1)

Publication Number Publication Date
AT260974T true AT260974T (en) 2004-03-15

Family

ID=24148714

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91912653T AT260974T (en) 1990-06-15 1991-06-17 Transgenic, non-human mammal that shows the amyloid-forming pathology of alzheimer's disease

Country Status (9)

Country Link
US (1) US5387742A (en)
EP (1) EP0647268B1 (en)
JP (1) JPH06507782A (en)
AT (1) AT260974T (en)
AU (1) AU646877B2 (en)
CA (1) CA2085127C (en)
DE (2) DE69133372T2 (en)
ES (1) ES2217250T3 (en)
WO (1) WO1991019810A1 (en)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264915B1 (en) 1992-09-13 2001-07-24 The President And Fellows Of Harvard College Process for detecting potential carcinogens
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
DK0971033T3 (en) * 1991-01-21 2009-12-14 Elan Pharm Inc Test and model for Alzheimer's disease
US5672805A (en) * 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
WO1993007296A1 (en) * 1991-10-03 1993-04-15 Indiana University Foundation Method for screening for alzheimer's disease
AU2861892A (en) * 1991-10-04 1993-05-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Astrocyte-specific transcription of human genes
JPH07506720A (en) * 1992-01-07 1995-07-27
US5604131A (en) * 1992-01-07 1997-02-18 Athena Neurosciences, Inc. cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
PT730643E (en) 1993-10-27 2001-06-29 Lilly Co Eli App transportation alge transgenic animals with swedish mutacao
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
JP3553592B2 (en) * 1992-10-26 2004-08-11 ビー. シェンク,デイル Methods and compositions for the detection of soluble β-amyloid peptide
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
CA2125467C (en) * 1993-07-06 2001-02-06 Heinz Dobeli Process for producing hydrophobic polypeptides, proteins or peptides
GB2295395B (en) * 1993-08-12 1998-04-01 Inst Of Psychiatry Models of Alzheimer's disease
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
JPH07132033A (en) * 1993-11-12 1995-05-23 Hoechst Japan Ltd Transgenic animal for alzheimer's disease model
EP0742831B1 (en) * 1994-01-27 2004-09-29 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6025183A (en) * 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
IL113052D0 (en) * 1994-03-23 1995-06-29 Rhone Poulenc Rorer Sa Recombinant viruses, their preparation and their use in gene therapy
US5792901A (en) * 1994-05-13 1998-08-11 The Regents Of The University Of California Detecting prions in a sample and prion preparation and transgenic animal used for same
US6020537A (en) * 1994-05-13 2000-02-01 The Regents Of The University Of California Prion protein standard and method of making same
US6008435A (en) * 1994-05-13 1999-12-28 The Regents Of The University Of California Detecting cow, sheep and human prions in a sample and transgenic mice used for same
WO1995034640A1 (en) * 1994-06-13 1995-12-21 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
US5686269A (en) * 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US6211428B1 (en) * 1994-09-01 2001-04-03 Merck & Co., Inc. Transgenic mouse expressing a familial form of human amyloid precursor protein
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5698766A (en) * 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
US5817911A (en) * 1995-04-07 1998-10-06 Regents Of The University Of California Transgenic mice expressing alveolar MCP-1
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
EP0876483A1 (en) * 1996-01-26 1998-11-11 HSC Research and Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
WO1996035126A1 (en) 1995-05-03 1996-11-07 President And Fellows Of Harvard College Assessing calcineurin's role in immunosuppression and neurotoxicity
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5858661A (en) * 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
EP0842188A4 (en) * 1995-07-18 2001-06-20 Univ Washington Mutant s182 genes
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
CA2227306A1 (en) * 1995-09-01 1997-03-27 Sara Lavi Manipulation and detection of protein phosphatase 2c - pp2c.alpha. - expression in tumor cells for cancer therapy, prevention and detection
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
AU4353696A (en) 1996-01-09 1997-08-01 Regents Of The University Of California, The Ungulate embryonic stem-like cells, making and using the cells to produce transgenic ungulate
WO1997025412A1 (en) 1996-01-09 1997-07-17 The Regents Of The University Of California Ungulate embryonic stem-like cells, methods of making and using the cells to produce transgenic ungulates
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
CA2259123C (en) 1996-07-01 2003-10-21 Jim A. Wright Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
DE69735498T2 (en) 1996-09-26 2006-11-09 The Regents Of The University Of Colorado, Boulder Transgenic model for heart failure
US5849999A (en) * 1996-10-16 1998-12-15 The Mclean Hospital Corporation Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
JP2001512973A (en) * 1997-02-24 2001-08-28 サイオス・インコーポレイテッド Improved assays β- amyloid processing
US5962669A (en) * 1997-06-02 1999-10-05 The Regents Of The University Of California Nucleic acid encoding prion protein variant
WO1998055132A1 (en) 1997-06-02 1998-12-10 The Regents Of The University Of California Prion protein modulator factor (ppmf) and prion resistant animals
US7973156B2 (en) * 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
EP1015471A1 (en) 1997-08-21 2000-07-05 Quark Biotech, Inc. Hypoxia-regulated genes
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6455757B1 (en) 1997-10-08 2002-09-24 The Regents Of The University Of California Transgenic mice expressing human APP and TGF-β demonstrate cerebrovascular amyloid deposits
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
AU2223899A (en) 1998-01-12 1999-07-26 Georgetown University Medical Center G protein-related kinase mutants in essential hypertension
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
MX343200B (en) 1998-11-27 2016-10-19 Ucb Pharma Sa Compositions and methods for increasing bone mineralization.
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2200900A (en) * 1998-12-22 2000-07-12 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative disorders
EP1026251A3 (en) * 1999-02-03 2000-09-06 Pfizer Products Inc. Transgenic animals expressing human P25
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20030131364A1 (en) * 1999-04-27 2003-07-10 Karen Duff Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
US6670195B1 (en) 1999-05-26 2003-12-30 New York University Mutant genes in Familial British Dementia and Familial Danish Dementia
US20070160615A1 (en) * 1999-06-01 2007-07-12 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
US6787318B1 (en) 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
WO2000072876A2 (en) * 1999-06-01 2000-12-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
EP1534345A4 (en) * 2002-07-12 2012-03-21 Yissum Res Dev Co Method and device for inducing biological processes by micro-organs
CA2377541A1 (en) * 1999-06-25 2001-01-04 Eduardo N. Mitrani Method of inducing angiogenesis by micro-organs
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
AU2579401A (en) * 1999-12-17 2001-06-25 Johns Hopkins University, The Brain protein markers
WO2001053323A2 (en) * 2000-01-24 2001-07-26 Ramot University Authority For Applied Research & Industrial Development Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
AT343562T (en) * 2000-03-23 2006-11-15 Elan Pharm Inc Compounds and method for the treatment of alzheimer's disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc REPLACED amine compounds as inhibitors of beta-secretase FOR TREATING ALZHEIMER
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
HU0300810A2 (en) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Értranszplantátum artificial, and its establishment and implementation
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
AT463560T (en) * 2000-09-28 2010-04-15 Bioriginal Food & Science Corp Fad4, fad5, fad5-2, and fad6, members of the fatty acid family family and its uses
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030051266A1 (en) * 2001-02-14 2003-03-13 Serafini Tito Andrew Collections of transgenic animal lines (living library)
EP2194133B1 (en) 2003-03-06 2015-12-02 BASF Enzymes LLC Amylases, nucleic acids encoding them and methods for making and using them
US7081561B2 (en) * 2001-03-16 2006-07-25 The Regents Of The University Of California Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
WO2002076189A1 (en) * 2001-03-22 2002-10-03 Scentgene Pollination Ltd. Method of enhancing entomophilous
DE60228477D1 (en) 2001-05-08 2008-10-02 Darwin Molecular Corp Process for regulating the immune function in primates using the foxp3 protein
WO2002098849A2 (en) 2001-06-01 2002-12-12 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
EP1395251A2 (en) 2001-06-13 2004-03-10 Elan Pharmaceuticals, Inc. Aminediols as agents for the treatment of alzheimer's disease
JP2005500319A (en) * 2001-06-27 2005-01-06 イーラン ファーマスーティカルズ、インコーポレイテッド Β-hydroxyamine derivatives useful for the treatment of Alzheimer's disease
JP2005505517A (en) * 2001-07-10 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド Aminediol for the treatment of Alzheimer's disease
MXPA04000338A (en) * 2001-07-10 2004-07-23 Upjohn Co Diaminediols for the treatment of alzheimer's disease.
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
EP1578987A2 (en) * 2001-08-03 2005-09-28 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US20040006092A1 (en) * 2001-08-31 2004-01-08 Neurochem, Inc. Amidine derivatives for treating amyloidosis
BR0213139A (en) * 2001-10-04 2004-08-10 Elan Pharm Inc Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
JP2005520791A (en) * 2001-11-08 2005-07-14 イーラン ファーマスーティカルズ、インコーポレイテッド N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214297A (en) * 2001-11-19 2004-11-09 Upjohn Co Methods of treating or preventing alzheimer's disease in an individual is a disease distinguished by beta-amyloid deposits on or in the brain, treating alzheimer's disease in an individual who has, or preventing an individual from acquiring a disease or condition from inhibit beta-secretase activity, cleavage of an amyloid precursor protein isotype and production of beta-amyloid peptide and beta-amyloid plaque in an animal and to produce a beta-secretase complex and use of a compound, and, composition
AU2002358947A1 (en) * 2001-12-05 2003-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US7067321B2 (en) * 2002-02-22 2006-06-27 University Of Tennessee Research Foundation Polyglutamine repeat sequences
ES2392247T3 (en) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Immunizing compound and method for inducing an immune response against the cleavage site of amyloid precursor protein beta-secretase
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
CN1659276A (en) 2002-04-19 2005-08-24 戴弗萨公司 Phospholipases, nucleic acids encoding them and methods for making and using them
US7262208B2 (en) * 2002-04-30 2007-08-28 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of Alzheimer's disease
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
US20040005571A1 (en) * 2002-07-03 2004-01-08 Hawley R. Scott Axs gene and protein and methods related thereto
UY27967A1 (en) * 2002-09-10 2004-05-31 Pfizer 2-Acetyl-1,3-diaminoalkanes hindroxi
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2004042363A2 (en) * 2002-11-04 2004-05-21 Dana-Farber Cancer Institute, Inc. In vivo imaging of e2f-regulated bioluminescent proteins
EP1572730A4 (en) * 2002-11-22 2006-04-19 Med College Georgia Res Inst Nact as a target for lifespan expansion and weight reduction
JP2006508166A (en) * 2002-11-27 2006-03-09 イーラン ファーマスーティカルズ、インコーポレイテッド Substituted ureas and carbamates
ES2545765T3 (en) * 2003-02-01 2015-09-15 Janssen Sciences Ireland Uc Active immunization to generate antibodies to soluble A-beta
CA3007908A1 (en) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
HUE030493T2 (en) 2003-04-04 2017-05-29 Basf Enzymes Llc Pectate lyases, Nucleic Acids encoding them and methods for making and using them
EP1615915A1 (en) * 2003-04-21 2006-01-18 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
CA2523232A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease
JP4847868B2 (en) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド Compounds and their use in the regulation of amyloid beta
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7588767B2 (en) 2003-06-18 2009-09-15 Genelux Corporation Microorganisms for therapy
CA2529403C (en) 2003-07-02 2016-02-16 Diversa Corporation Glucanases, nucleic acids encoding them and methods for making and using them
WO2005010039A1 (en) * 2003-07-31 2005-02-03 Pfizer Products Inc. Bsep polypeptide variants and uses thereof
US7741089B2 (en) 2003-08-11 2010-06-22 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
EP1729755A1 (en) * 2004-01-21 2006-12-13 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2005087215A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
EP1734961A2 (en) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
EP1730125A2 (en) * 2004-03-09 2006-12-13 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2558036A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005114217A2 (en) * 2004-04-20 2005-12-01 Medical College Of Georgia Research Institute, Inc. Na+ and ci> coupled transport system for endogenous opioid peptides
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
EP1750719A2 (en) * 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Treatment of diseases associated with altered level of amyloid beta peptides
ES2461857T3 (en) 2004-06-16 2014-05-21 Dsm Ip Assets B.V. Compositions and methods for enzymatic discoloration of chlorophyll
AU2005265354A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
CA2573138A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006026533A2 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
AR051800A1 (en) * 2004-12-15 2007-02-07 Wyeth Corp Beta antibodies used to improve cognition
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
DK2332408T3 (en) 2005-02-17 2013-12-02 Biogen Idec Inc Treatment of neurological diseases
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
CN102943085A (en) 2005-03-15 2013-02-27 维莱尼姆公司 Cellulases, nucleic acids encoding them and methods for making and using them
WO2006128163A2 (en) * 2005-05-27 2006-11-30 Memory Pharmaceuticals Corp. Transgenic alzheimer's mouse model vectors and uses thereof
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
WO2007017511A2 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
EP1915353A2 (en) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Isophthalic acid diamides for treating alzheimer disease
EP1915352A1 (en) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Compounds for the treatment of alzheimer's disease
EP1915339A1 (en) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Beta-secretase inhibitors for use in the treatment of alzheimer's disease
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
CA2624904A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
JP2009525110A (en) 2006-01-31 2009-07-09 マルチ ジーン バスキュラー システムズ, インコーポレイテッド Drug-eluting endovascular prostheses and methods of use
EP2216403A3 (en) 2006-02-02 2010-11-24 Verenium Corporation Esterases and related nucleic acids and methods
WO2007092854A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7932261B2 (en) * 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
EP2444487B1 (en) 2006-02-10 2018-04-18 BP Corporation North America Inc. Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
CA2946924A1 (en) 2006-02-14 2007-08-23 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
BRPI0708493A2 (en) * 2006-03-01 2011-05-31 Roskamp Res Llc compounds for inhibiting beta-amyloid production
EP1994161A2 (en) 2006-03-07 2008-11-26 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
EA029538B1 (en) 2006-03-07 2018-04-30 Басф Энзаймс Ллк Polypeptide having aldolase activity, polynucleotide encoding this polypeptide and methods for making and using the polynucleotide and polypeptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009020459A2 (en) 2006-08-04 2009-02-12 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
AU2007294858B2 (en) 2006-09-14 2011-05-12 Medgenics Medical Israel, Ltd Long lasting drug formulations
WO2008036863A2 (en) 2006-09-21 2008-03-27 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
HUE029140T2 (en) 2006-09-21 2017-02-28 Basf Enzymes Llc Phytases, nucleic acids encoding them and methods for making and using them
KR20170061720A (en) 2006-10-12 2017-06-05 비에이치아이 리미티드 파트너쉽 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8188046B2 (en) * 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
EP2120557A4 (en) * 2006-12-08 2010-02-10 Roskamp Res Llc Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production
EP2479267B1 (en) 2006-12-21 2016-12-21 BASF Enzymes LLC Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them
WO2008106657A2 (en) * 2007-03-01 2008-09-04 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
EP2134863B1 (en) 2007-03-13 2014-05-21 The Children's Hospital Of Philadelphia Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis of type 1 diabetes
WO2008152507A2 (en) 2007-03-16 2008-12-18 Multigene Vascular Systems, Inc. Compositions and methods for treating ophthalmic disorders
EP2144935A2 (en) 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2146746A4 (en) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap Prevention and treatment of cerebral amyloid angiopathy
WO2009007300A2 (en) 2007-07-06 2009-01-15 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
JP5889529B2 (en) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー Treatment of amyloidogenic diseases
CA2696934A1 (en) * 2007-09-12 2010-02-16 Probiodrug Ag Transgenic mice
CN101952437B (en) 2007-10-03 2014-04-09 维莱尼姆公司 Xylanases, nucleic acids encoding them and methods for making and using them
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
JP2011502162A (en) * 2007-10-29 2011-01-20 ザ ユニバーシティー オブ カリフォルニア Osteoarthritis gene therapy
ES2531290T3 (en) 2008-01-03 2015-03-12 Basf Enzymes Llc Transferases and oxidoreductases, nucleic acids that encode them and methods to prepare and use them
US8541220B2 (en) 2008-01-03 2013-09-24 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
KR20100107045A (en) * 2008-01-28 2010-10-04 얀센 파마슈티카 엔.브이. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
JP2011510993A (en) * 2008-01-29 2011-04-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap 2-Amino-quinoline derivatives useful as β-secretase (BACE) inhibitors
EP2257643B1 (en) 2008-02-19 2015-04-08 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
JP6095889B2 (en) 2008-05-16 2017-03-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Chromosome 21q, 6q, and 15q gene mutations and methods for using them to diagnose and treat type 1 diabetes
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
KR20110056323A (en) 2008-09-15 2011-05-26 제넨테크, 인크. Compositions and methods for regulating cell osmolarity
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2698374T3 (en) 2009-05-21 2017-01-09 Basf Enzymes Llc Phytases, nucleic acids encoding them, and methods of making and using the same
US8324450B2 (en) 2009-06-02 2012-12-04 Academia Sinica Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
BR112012008957A2 (en) 2009-10-16 2017-09-19 Dsm Ip Assets Bv phospholipases, nucleic acids encoding them and methods for making and using them
MY162429A (en) 2009-10-16 2017-06-15 Bunge Oils Inc Oil degumming methods
CN103260649A (en) 2010-06-15 2013-08-21 迈德詹尼克斯医疗以色列有限公司 Long lasting drug formulations
EP2605655B1 (en) 2010-08-19 2018-10-24 Buck Institute for Age Research Methods of treating mild cognitive impairment (mci) and related disorders
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
JP6406581B2 (en) 2011-12-16 2018-10-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Opsin polypeptides and uses thereof
CA2921221A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
EP3060144A1 (en) 2013-10-24 2016-08-31 Medgenics Medical Israel, Ltd Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
US10052383B2 (en) 2014-03-28 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University Engineered light-activated anion channel proteins and methods of use thereof
KR101890978B1 (en) 2014-06-17 2018-08-24 서울대학교산학협력단 Transgenic cloned porcine Models for alzheimer's disease and the Use thereof
EP3212811A4 (en) 2014-10-29 2018-08-08 The Children's Hospital of Philadelphia Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
KR20170084332A (en) 2014-12-04 2017-07-19 노파르티스 아게 Methods and compositions using klotho variant polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3055889A (en) * 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic sequences coding for alzheimer amyloid from brain
AU3056289A (en) * 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
EP0451700A1 (en) * 1990-04-10 1991-10-16 Miles Inc. Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
WO1992006187A1 (en) * 1990-09-28 1992-04-16 The Upjohn Company Transgenic animals with alzheimer's amyloid precursor gene
US5672805A (en) * 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein

Also Published As

Publication number Publication date
JPH06507782A (en) 1994-09-08
WO1991019810A1 (en) 1991-12-26
ES2217250T3 (en) 2004-11-01
AU8210291A (en) 1992-01-07
CA2085127A1 (en) 1991-12-16
AU646877B2 (en) 1994-03-10
DE69133372T2 (en) 2005-02-24
EP0647268A4 (en) 1993-05-27
DE69133372D1 (en) 2004-04-08
EP0647268A1 (en) 1995-04-12
CA2085127C (en) 2002-12-10
US5387742A (en) 1995-02-07
EP0647268B1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
DE69333740D1 (en) Device for shaping the cornea
DE69428644T2 (en) Mold for lenses
DE69331614T2 (en) Optical reader
DE69133396D1 (en) Warenauszahlsystem
DE69232515T2 (en) enzymorthokeratologie
GB2250995B (en) Multivalent antigen-binding proteins
DE69209091T3 (en) Trockenrasiergerät
DE69332522D1 (en) Mechanical toothbrush
DE69233729D1 (en) Shavers
DE69233768D1 (en) Retinsäurederivate
GB2048758B (en) Cotact lens mould
DE3856537D1 (en) The image recording device
DE69233160D1 (en) Selbstinduzierer
DE69525223D1 (en) Grating filter in the optical waveguide
DE69233370D1 (en) Entwicklernachfüllcontainer
DE69133443D1 (en) Electromagnetic converters
DE69232302D1 (en) 7-Substituted-9-substituted amino-6-demethyl-6-deoxy-tetracyclines
DK0504363T4 (en) Purified IgG antibodies
DE69332859T2 (en) Consensus-kozak sequences for mammal expression
DE69332458T2 (en) vector processor
DE69114013T3 (en) Wave riding attraction.
DK0972526T3 (en) Manufacture of diagnostic agents
DK0971033T3 (en) Test and model for Alzheimer&#39;s disease
DE69232983T2 (en) Adeno-associated virus 2 basal vectors
DE69133397D1 (en) benzoyl

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties